Contact the Editorial Desk

Editorial correspondence

This desk welcomes notes on the record itself: a citation quoted imprecisely, a clinical trial that has posted new results, a regulatory update affecting semaglutide's approved indications, or a peer-reviewed study on semaglutide, AOD-9604, or MOTS-c that belongs on the references page. Notes that name the specific page, the passage in question, and a supporting reference — a DOI or PubMed identifier where available — are the easiest to check and act on.

Editorial mailbox: editors@metabolixpeptides.com

What this desk can't help with

Because this site reports the literature rather than practicing medicine or selling anything, it cannot: weigh in on or advise human use of any peptide covered here; name a dose, schedule, or route for any individual; judge whether a finding from a cited trial applies to a specific person's situation; or help source, supply, or track down any compound from any vendor. Semaglutide is a prescription medicine available only through a licensed provider; AOD-9604 is a discontinued drug candidate; MOTS-c has no completed human trial and no established human dose. Anyone seeking medical guidance should bring that question to a licensed clinician in their own jurisdiction. Replies aren't guaranteed and can take time; the mailbox is checked periodically.